Trial Profile
Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Paxalisib (Primary) ; Trastuzumab (Primary)
- Indications Brain metastases; Breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 06 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2024.
- 02 Mar 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.
- 10 Dec 2020 According to an Kazia Therapeutics media release, Dana-Farber Cancer Institute is sponsor of this trial.